Keywords: mabthera, track, first-line, use, nhl, european, union

MabThera on track for first-line use in NHL

Article | 05 July 2004

Print This

The European Union's Committee for Human Medicinal Products has issued apositive opinion for the first-line use of Roche's MabThera (Rituxan; ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in